Citi downgrades Boston Scientific as cyberattack recovery compounds competitive pressure
Citi downgraded Boston Scientific (BSX) to neutral, citing uncertainty from a recent cyberattack and competitive pressures. The firm lowered its target price to $50 and expects declines in Watchman and Farapulse sales. BSX shares have fallen 13% in a month, underperforming the S&P 500.
How this was made
The 30-second read
Why it matters
Analyst downgrade reflects uncertainty around recovery timeline and competitive dynamics in Watchman and Farapulse product lines.
Market read
The downgrade adds fresh negative sentiment to BSX and may influence broader med‑tech sector positioning.
What to watch
Potential upside from upcoming FDA submissions for Seismiq and Tivus platforms.
Background
Boston Scientific recently recovered from a global network outage caused by a cyberattack on August 25, restoring operations and order backlog.
Ticker impact
Citi downgraded Boston Scientific to neutral and cut the target price to $50, citing cyber‑attack fallout and competitive pressure.
downward pressure on BSX price in the near term
The downgrade is a fresh, material change from buy to neutral with a $7 target price reduction, which historically moves mid‑cap stocks.
Market effects
Highlights heightened risk for cardiac device makers facing cyber‑security and competitive pressures.
US healthcare equipment sector may see modest pullback.
Limited to investors tracking med‑tech equities.
Counterpoint
The cyber‑attack impact may be overstated; long‑term pipeline remains strong.
Key entities
- CompanyBoston Scientific
Medical device manufacturer (NYSE:BSX).
- AnalystCiti
Downgraded BSX to neutral and cut target price.
